A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity

Awadalkareem Adam, Birte Kalveram, John Yun Chung Chen, Jason Yeung, Leslie Rodriguez, Ankita Singh, Pei Yong Shi, Xuping Xie, Tian Wang

Research output: Contribution to journalArticlepeer-review

Abstract

An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.

Original languageEnglish (US)
Article number160
Journalnpj Vaccines
Volume8
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity'. Together they form a unique fingerprint.

Cite this